Arax Advisory Partners’s AYTU BioPharma AYTU Stock Holding History

Arax Advisory Partners’s Portfolio AYTU Stock Details AYTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4	Buy	+2	New	+$5	﹤0.01%	5197
2021 Q4	–	Hold	0	–	–	–	1140
2021 Q3	–	Hold	0	–	–	–	993
2021 Q2	–	Hold	0	–	–	–	916

Other funds holding AYTU

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Crown Advisors Management Larkspur, California $182M AUM 103.97% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Arax Advisory Partners's AYTU Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in AYTU BioPharma (AYTU) in Q2 2026: 2 shares worth $4. The stake represents ﹤0.01% of the portfolio and ranks #5197 among its holdings.

38 funds tracked by Wall St. Rank hold AYTU as of Q2 2026.

Arax Advisory Partners held 2 shares of AYTU BioPharma worth $4 as of Q2 2026.
AYTU BioPharma was a new Arax Advisory Partners position in Q2 2026.
AYTU BioPharma made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #5197 holding.
38 funds tracked by Wall St. Rank held AYTU BioPharma as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.